keyword
MENU ▼
Read by QxMD icon Read
search

future lung cancer

keyword
https://www.readbyqxmd.com/read/27904842/the-challenges-of-cardiothoracic-surgery-practice-in-nigeria-a-12-years-institutional-experience
#1
Bode Falase, Michael Sanusi, Adeola Animasahun, Ogadinma Mgbajah, Adetinuwe Majekodunmi, Onyekwelu Nzewi, Jonathan Nwiloh, David Oke
BACKGROUND: Although the specialty of cardiothoracic surgery has been practiced in Nigeria for many years, open heart surgery (OHS) has only in the last decade become relatively more frequent, mainly through visiting foreign cardiac surgical teams. At this early phase of development it is faced with multiple challenges, especially financing and local skilled manpower for which solutions have to be identified in order to ensure sustainability and future growth. This study is aimed at highlighting these obstacles to growth of cardiothoracic surgery based on our own institutional experience at Lagos State University Teaching Hospital (LASUTH) and the current status of OHS activity in other cardiothoracic centers in Nigeria...
October 2016: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/27903834/saliva-diagnostics-current-views-and-directions
#2
Karolina Elżbieta Kaczor-Urbanowicz, Carmen Martin Carreras-Presas, Katri Aro, Michael Tu, Franklin Garcia-Godoy, David Tw Wong
In this review, we provide an update on the current and future applications of saliva for diagnostic purposes. There are many advantages of using saliva as a biofluid. Its collection is fast, easy, inexpensive, and non-invasive. In addition, saliva, as a "mirror of the body," can reflect the physiological and pathological state of the body. Therefore, it serves as a diagnostic and monitoring tool in many fields of science such as medicine, dentistry, and pharmacotherapy. Introduced in 2008, the term "Salivaomics" aimed to highlight the rapid development of knowledge about various "omics" constituents of saliva, including: proteome, transcriptome, micro-RNA, metabolome, and microbiome...
November 29, 2016: Experimental Biology and Medicine
https://www.readbyqxmd.com/read/27899957/next-generation-sequencing-in-nsclc-and-melanoma-patients-a-cost-and-budget-impact-analysis
#3
Rosa A van Amerongen, Valesca P Retèl, Veerle Mh Coupé, Petra M Nederlof, Maartje J Vogel, Wim H van Harten
Next-generation sequencing (NGS) has reached the molecular diagnostic laboratories. Although the NGS technology aims to improve the effectiveness of therapies by selecting the most promising therapy, concerns are that NGS testing is expensive and that the 'benefits' are not yet in relation to these costs. In this study, we give an estimation of the costs and an institutional and national budget impact of various types of NGS tests in non-small-cell lung cancer (NSCLC) and melanoma patients within The Netherlands...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27893446/stability-of-radiomic-features-in-ct-perfusion-maps
#4
M Bogowicz, O Riesterer, R A Bundschuh, P Veit-Haibach, M Hüllner, G Studer, S Stieb, S Glatz, M Pruschy, M Guckenberger, S Tanadini-Lang
This study aimed to identify a set of stable radiomic parameters in CT perfusion (CTP) maps with respect to CTP calculation factors and image discretization, as an input for future prognostic models for local tumor response to chemo-radiotherapy. Pre-treatment CTP images of eleven patients with oropharyngeal carcinoma and eleven patients with non-small cell lung cancer (NSCLC) were analyzed. 315 radiomic parameters were studied per perfusion map (blood volume, blood flow and mean transit time). Radiomics robustness was investigated regarding the potentially standardizable (image discretization method, Hounsfield unit (HU) threshold, voxel size and temporal resolution) and non-standardizable (artery contouring and noise threshold) perfusion calculation factors using the intraclass correlation (ICC)...
December 21, 2016: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/27892978/estimating-survival-in-patients-with-lung-cancer-and-brain-metastases-an-update-of-the-graded-prognostic-assessment-for-lung-cancer-using-molecular-markers-lung-molgpa
#5
Paul W Sperduto, T Jonathan Yang, Kathryn Beal, Hubert Pan, Paul D Brown, Ananta Bangdiwala, Ryan Shanley, Norman Yeh, Laurie E Gaspar, Steve Braunstein, Penny Sneed, John Boyle, John P Kirkpatrick, Kimberley S Mak, Helen A Shih, Alex Engelman, David Roberge, Nils D Arvold, Brian Alexander, Mark M Awad, Joseph Contessa, Veronica Chiang, John Hardie, Daniel Ma, Emil Lou, William Sperduto, Minesh P Mehta
Importance: Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. As systemic therapies improve, patients with lung cancer live longer and thus are at increased risk for brain metastases. Understanding how prognosis varies across this heterogeneous patient population is essential to individualize care and design future clinical trials. Objective: To update the current Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases...
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27888157/curcumin-use-in-pulmonary-diseases-state-of-the-art-and-future-perspectives
#6
REVIEW
Diana Lelli, Amirhossein Sahebkar, Thomas P Johnston, Claudio Pedone
Curcumin (diferuloylmethane) is a yellow pigment present in the spice turmeric (Curcuma longa). It has been used for centuries in Ayurveda (Indian traditional medicine) for the treatment of several diseases. Over the last several decades, the therapeutic properties of curcumin have slowly been elucidated. It has been shown that curcumin has pleiotropic effects, regulating transcription factors (e.g., NF-kB), cytokines (e.g., IL6, TNF-alpha), adhesion molecules (e.g., ICAM-1), and enzymes (e.g., MMPs) that play a major role in inflammation and cancerogenesis...
November 22, 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27885858/a-systematic-review-of-outcomes-following-stereotactic-ablative-radiotherapy-in-the-treatment-of-early-stage-primary-lung-cancer
#7
Patrick Murray, Kevin Franks, Gerard G Hanna
Stereotactic ablative body radiotherapy (SABR) describes a radiotherapy technique where high doses of radiation are precisely delivered to an extra-cranial target within the body, using either a single fraction of radiotherapy or using multiple small number of fractions. SABR has now become the standard of care treatment for patients with early stage NSCLC for whom surgery is not appropriate. This systematic review considers the evidence supporting the use of SABR in early stage NSCLC, reported toxicity rates, the use of SABR in centrally located NSCLC, the use of SABR as salvage therapy following surgery or radiotherapy and future potential drug combinations with SABR...
November 25, 2016: British Journal of Radiology
https://www.readbyqxmd.com/read/27885857/dosimetric-trade-offs-in-breast-treatment-with-vmat-technique
#8
Antonella Fogliata, Jan Seppälä, Giacomo Reggiori, Francesca Lobefalo, Valentina Palumbo, Fiorenza De Rose, Davide Franceschini, Marta Scorsetti, Luca Cozzi
OBJECTIVES: Breast planning with volumetric modulated arc therapy (VMAT) has been explored, especially for left sided breast treatments, with the primary intent of lowering the heart dose and improving target dose homogeneity. As a trade-off, larger healthy tissue volumes would receive low dose levels, with the potential risk of increasing late toxicities and secondary cancer induction, although no clinical data are today available to confirm the risk level. Scope of this work is to explore the dosimetric trade-offs using two different VMAT planning...
November 25, 2016: British Journal of Radiology
https://www.readbyqxmd.com/read/27885838/osimertinib-for-egfr-t790m-mutation-positive-non-small-cell-lung-cancer
#9
Kenzo Soejima, Hiroyuki Yasuda, Toshiyuki Hirano
Significant advances have been made since the development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) targeting EGFR mutations in non-small-cell lung cancer (NSCLC), however, lung cancer cells eventually acquire resistance to those agents. Osimertinib (AZD9291) has been developed as 3(rd) generation EGFR-TKI with activities against sensitizing mutations and T790M resistance mutation, which account for about 50% of the mechanisms of acquired resistance to 1(st) or 2(nd) generation EGFR-TKIs...
November 25, 2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/27879970/mortality-hospital-days-and-expenditures-attributable-to-ambient-air-pollution-from-particulate-matter-in-israel
#10
Gary M Ginsberg, Ehud Kaliner, Itamar Grotto
BACKGROUND: Worldwide, ambient air pollution accounts for around 3.7 million deaths annually. Measuring the burden of disease is important not just for advocacy but also is a first step towards carrying out a full cost-utility analysis in order to prioritise technological interventions that are available to reduce air pollution (and subsequent morbidity and mortality) from industrial, power generating and vehicular sources. METHODS: We calculated the average national exposure to particulate matter particles less than 2...
2016: Israel Journal of Health Policy Research
https://www.readbyqxmd.com/read/27878432/histopathologic-diagnosis-of-brain-metastases-current-trends-in-management-and-future-considerations
#11
Lien Bekaert, Evelyne Emery, Guénaëlle Levallet, Emmanuèle Lechapt-Zalcman
Confronted with brain metastases (BM), pathologists aim to rule out a primary central nervous system (CNS) tumor and to identify or verify the primary tumor site to guide the clinician to specific therapies. Apart from morphological features, ancillary immunohistochemical analysis is the most effective tool for characterizing a metastatic neoplasm of unknown origin. A limited array of antibodies is used, taking into account relevant clinical information and the known brain tropism of lung cancer, breast cancer and melanoma...
November 22, 2016: Brain Tumor Pathology
https://www.readbyqxmd.com/read/27877227/incidence-and-predictors-of-bone-metastases-bm-and-skeletal-related-events-sres-in-small-cell-lung-cancer-sclc-a-swiss-patient-cohort
#12
Katrin Conen, Raphael Hagmann, Viviane Hess, Alfred Zippelius, Sacha I Rothschild
Objectives: Bone metastases (BM) and skeletal-related events (SREs) are frequent complications in patients with lung cancer. Whereas in non-small-cell lung cancer (NSCLC) incidence, prognostic impact, and risk factors are well established, there is only little knowledge in patients with small cell lung cancer (SCLC). We retrospectively evaluated the incidence of BM, SRE and their treatment in a SCLC patient cohort treated at our hospital. We further assessed the role of Lactate Dehydrogenase (LDH), a possible predictor of BM development in SCLC patients...
2016: Journal of Cancer
https://www.readbyqxmd.com/read/27876462/expression-and-clinicopathological-significance-of-s100-calcium-binding-protein-a2-in-lung-cancer-patients-of-chinese-han-ethnicity
#13
Ting Wang, Yiqian Liang, Asmitananda Thakur, Shuo Zhang, Feng Liu, Hamadhaider Khan, Puyu Shi, Ning Wang, Mingwei Chen, Hui Ren
BACKGROUND: S100 family of calcium-binding proteins plays a significant role in the process of many kinds of tumors, including lung cancer. As an important member of this family, S100 calcium binding protein A2 (S100A2) has been confirmed to be associated with many biological processes, and has an abnormal expression in non-small cell lung cancer (NSCLC). However, the S100A2 status in lung cancer is still controversial and undefined. METHODS: We evaluated the pattern and distribution of S100A2 in 109 cases of lung cancer, including five histological types (47 adenocarcinoma, 46 squamous cell carcinoma, 7 small cell carcinoma, 3 large cell carcinoma, and 6 atypical carcinoid), and 30 cases of paired adjacent normal lung tissues by means of immunohistochemistry...
November 19, 2016: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/27874949/mir-377-inhibited-tumorous-behaviors-of-non-small-cell-lung-cancer-through-directly-targeting-cdk6
#14
J Zhang, M Zhao, Z-Q Xue, Y Liu, Y-X Wang
OBJECTIVE: This study is aimed to investigate the cellular role of miR-377 and demonstrate that miR-377 negatively regulated cyclin-dependent kinase 6(CDK6) in human non-small cell lung cancer (NSCLC) cells. MATERIALS AND METHODS: qRT-PCR was performed to identify the miR-377 expression level in 45 paired NSCLC and adjacent normal lung tissues. Cell proliferation was measured by MTT. Apoptosis was detected by flow cytometric analysis. Luciferase reporter assays were employed to validate regulation of a putative target of miR-377...
November 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27874172/development-of-crizotinib-a-rationally-designed-tyrosine-kinase-inhibitor-for-non-small-cell-lung-cancer
#15
REVIEW
Candice C Poon, John J Kelly
Non-small cell lung cancer (NSCLC) is the number one cause of global mortality. Despite aggressive treatment, the prognosis is dismal. Patients with advanced NSCLC have a median survival of four months from the time of diagnosis. Fortunately, molecularly-based approaches to drug discovery have yielded a tyrosine kinase inhibitor, crizotinib, which significantly prolongs median progression free survival in a subset of patients. Although initial clinical trial results demonstrate crizotinib has a promising role to play in NSCLC treatment, development of resistance leaves much to be elucidated about how to effectively combat this deadly disease...
November 22, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27866520/-research-advancement-on-egfr-mutation-detection-of-cell-free-dna-and-tumor-cell-in-peripheral-blood-of-patients-with-non-small-cell-lung-cancer
#16
Yu Zhang, Yan Xu, Mengzhao Wang
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Epideral growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the most important treatments currently for advanced NSCLC patients harboring activating EGFR gene mutations, and achieve significant clinical efficacy. T790M mutation occurs in half of NSCLC patents with acquired EGFR-TKI resistance. Screening for EGFR gene mutations in histological and/or circulating tumor cell or DNA samples of NSCLC patients can identify patients who would have a response to EGFR-TKIs or acquire resistance during the treatment...
November 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27866095/continuing-egfr-inhibition-beyond-progression-in-advanced-non-small-cell-lung-cancer
#17
REVIEW
Timothy A Yap, Aislinn Macklin-Doherty, Sanjay Popat
The majority of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) respond to first-line EGFR tyrosine kinase inhibitors (TKIs), but nearly all inevitably acquire resistance and develop disease progression. Conventional practice would be to switch treatments to second-line therapy. However, continuing TKIs beyond progression is becoming increasingly commonplace in patients with indolent, small volume asymptomatic growth, who may potentially continue to derive ongoing clinical benefit and to avoid a 'withdrawal tumour flare'...
November 17, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27855495/pharmacological-importance-characterization-and-applications-of-gold-and-silver-nanoparticles-synthesized-by-panax-ginseng-fresh-leaves
#18
Priyanka Singh, Hina Singh, Sungeun Ahn, Verónica Castro-Aceituno, Zuly Jiménez, Shakina Yesmin Simu, Yeon Ju Kim, Deok Chun Yang
Previously, we showed the rapid and eco-friendly synthesis of gold and silver nanoparticles within 3 and 45 min by fresh leaves extract of herbal medicinal plant Panax ginseng. In addition, we characterized the nanoparticles in terms of shape, size, morphology and stability by FE-TEM, EDX, elemental mapping, SEAD, XRD and particles size analysis. In addition of this, we showed their antimicrobial, anti-coagulant, and biofilm inhibition activity of nanoparticles. Continuing our previous study, here we highlight the further characterization and biomedical applications of P...
November 18, 2016: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/27852073/anti-tumor-activity-of-high-dose-egfr-tyrosine-kinase-inhibitor-and-sequential-docetaxel-in-wild-type-egfr-non-small-cell-lung-cancer-cell-nude-mouse-xenografts
#19
Ning Tang, Qianqian Zhang, Shu Fang, Xiao Han, Zhehai Wang
Treatment of non-small-cell lung cancer (NSCLC) with wild-type epidermal growth factor receptor (EGFR) is still a challenge. This study explored antitumor activity of high-dose icotinib (an EGFR tyrosine kinase inhibitor) plus sequential docetaxel against wild-type EGFR NSCLC cells-generated nude mouse xenografts. Nude mice were subcutaneously injected with wild-type EGFR NSCLC A549 cells and divided into different groups for 3-week treatment. Tumor xenograft volumes were monitored and recorded, and at the end of experiments, tumor xenografts were removed for Western blot and immunohistochemical analyses...
November 12, 2016: Oncotarget
https://www.readbyqxmd.com/read/27846884/future-perspectives-in-melanoma-research-meeting-report-from-the-melanoma-bridge-napoli-december-1st-4th-2015
#20
Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, Alessandra Cesano, Gennaro Ciliberto, Michael A Davies, Sandra Demaria, Reinhard Dummer, Alexander M Eggermont, Soldano Ferrone, Yang Xin Fu, Thomas F Gajewski, Claus Garbe, Veronica Huber, Samir Khleif, Michael Krauthammer, Roger S Lo, Giuseppe Masucci, Giuseppe Palmieri, Michael Postow, Igor Puzanov, Ann Silk, Stefani Spranger, David F Stroncek, Ahmad Tarhini, Janis M Taube, Alessandro Testori, Ena Wang, Jennifer A Wargo, Cassian Yee, Hassane Zarour, Laurence Zitvogel, Bernard A Fox, Nicola Mozzillo, Francesco M Marincola, Magdalena Thurin
The sixth "Melanoma Bridge Meeting" took place in Naples, Italy, December 1st-4th, 2015. The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. Immunotherapies in particular have emerged as highly successful approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin's disease...
November 15, 2016: Journal of Translational Medicine
keyword
keyword
48858
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"